Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2185338rdf:typepubmed:Citationlld:pubmed
pubmed-article:2185338lifeskim:mentionsumls-concept:C0006413lld:lifeskim
pubmed-article:2185338lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:2185338lifeskim:mentionsumls-concept:C0023449lld:lifeskim
pubmed-article:2185338lifeskim:mentionsumls-concept:C0149615lld:lifeskim
pubmed-article:2185338lifeskim:mentionsumls-concept:C0677874lld:lifeskim
pubmed-article:2185338pubmed:issue5lld:pubmed
pubmed-article:2185338pubmed:dateCreated1990-6-1lld:pubmed
pubmed-article:2185338pubmed:abstractTextThe prognosis of adults with Burkitt's lymphoma is very poor and depends on initial CNS and/or bone marrow involvement. We report results in nine adult patients with CNS (n = 9) and/or bone marrow involvement (n = 7) treated in first complete remission (CR) with allogeneic bone marrow transplantation (BMT). CNS treatment before the conditioning regimen consisted of cranial irradiation at 15 Gy (n = 8) and intrathecal chemotherapy (n = 9). The conditioning regimen included cyclophosphamide and total body irradiation (TBI) in a single dose. No postgraft CNS prophylaxis was administered. At the present time, seven patients are alive and disease-free at 18, 23, 44, 47, 54, 54, and 59 months. Two patients died at 14 and 7 months from transfusion-related acquired immune deficiency syndrome and bacterial septicemia and were disease-free at the time of their death. These preliminary results should encourage the use of BMT. A prospective randomized trial is warranted to further specify and investigate the advantages of allogeneic BMT versus conventional chemotherapy.lld:pubmed
pubmed-article:2185338pubmed:languageenglld:pubmed
pubmed-article:2185338pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2185338pubmed:citationSubsetIMlld:pubmed
pubmed-article:2185338pubmed:statusMEDLINElld:pubmed
pubmed-article:2185338pubmed:monthMaylld:pubmed
pubmed-article:2185338pubmed:issn0732-183Xlld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:VernantJ PJPlld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:JouetJ PJPlld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:LeporrierMMlld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:KuentzMMlld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:CordonnierCClld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:TroussardXXlld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:LeblondVVlld:pubmed
pubmed-article:2185338pubmed:authorpubmed-author:MilpiedNNlld:pubmed
pubmed-article:2185338pubmed:issnTypePrintlld:pubmed
pubmed-article:2185338pubmed:volume8lld:pubmed
pubmed-article:2185338pubmed:ownerNLMlld:pubmed
pubmed-article:2185338pubmed:authorsCompleteYlld:pubmed
pubmed-article:2185338pubmed:pagination809-12lld:pubmed
pubmed-article:2185338pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:meshHeadingpubmed-meshheading:2185338-...lld:pubmed
pubmed-article:2185338pubmed:year1990lld:pubmed
pubmed-article:2185338pubmed:articleTitleAllogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remission.lld:pubmed
pubmed-article:2185338pubmed:affiliationBone Marrow Transplantation Unit, Caen, France.lld:pubmed
pubmed-article:2185338pubmed:publicationTypeJournal Articlelld:pubmed